List of Excipients in Branded Drug MAVIK

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	MAVIK	trandolapril	54868-5099	CROSCARMELLOSE SODIUM
Physicians Total Care Inc	MAVIK	trandolapril	54868-5099	FERRIC OXIDE RED
Physicians Total Care Inc	MAVIK	trandolapril	54868-5099	FERRIC OXIDE YELLOW
Physicians Total Care Inc	MAVIK	trandolapril	54868-5099	HYPROMELLOSES

MAVIK (Trandolapril) Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 11, 2026

MAVIK is the former U.S. brand for trandolapril, an oral angiotensin-converting enzyme inhibitor approved for hypertension. Its commercial value is now concentrated in generic manufacturing, lifecycle reformulation, combination products, and supply-chain differentiation rather than brand protection. The most practical excipient strategy is a conventional immediate-release tablet with improved moisture control, tighter content uniformity, and optional lactose-free or low-cost alternative formulations.

What is MAVIK and which drug substance does it contain?

MAVIK contains trandolapril, an ester prodrug converted in vivo to the active metabolite trandolaprilat. The product was approved for the treatment of hypertension and was supplied as immediate-release tablets in 0.5 mg, 1 mg, 2 mg, and 4 mg strengths.[1]

Attribute	MAVIK
Active ingredient	Trandolapril
Pharmacologic class	ACE inhibitor
Dosage form	Immediate-release oral tablet
Historical strengths	0.5 mg, 1 mg, 2 mg, 4 mg
U.S. indication	Hypertension
Reference product status	Legacy brand; generic competition established
Biologic risk	None
Primary regulatory pathway for generics	ANDA under section 505(j)
Combination product	Trandolapril/verapamil, marketed historically as TARKA

Trandolapril is a low-dose, potent API. The low dose creates a relatively high excipient-to-API ratio, making blend uniformity, segregation control, and assay validation more important than raw API loading.

What excipients are used in MAVIK tablets?

MAVIK labeling identifies conventional tablet excipients, including lactose monohydrate, microcrystalline cellulose, pregelatinized starch, crospovidone, colloidal silicon dioxide, and magnesium stearate. Strength-specific colorants may also be present.[1]

Excipient function	Typical MAVIK-related excipient	Commercial purpose
Diluent	Lactose monohydrate	Provides tablet mass and improves manufacturability
Secondary diluent	Microcrystalline cellulose	Supports compactibility and tablet hardness
Binder or dry binder	Pregelatinized starch	Improves granule and tablet cohesion
Disintegrant	Crospovidone	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow and reduces segregation
Lubricant	Magnesium stearate	Reduces punch and die adhesion
Appearance	Approved colorants	Supports strength identification and product differentiation

The formulation is not technically complex. Its principal development risks are low-dose uniformity, API distribution, tablet robustness, dissolution performance, and stability of the ester prodrug under heat and humidity.

How should a generic manufacturer design a trandolapril excipient system?

A generic formulation should begin with a direct-compression platform if the API has adequate flow and compressibility. A roller-compacted or wet-granulated process may be preferable when blend uniformity or tablet tensile strength is inadequate.

Recommended baseline formulation

A practical starting platform is:

• Microcrystalline cellulose as the principal compressibility aid
• Lactose monohydrate as a cost-effective diluent
• Crospovidone as the primary disintegrant
• Pregelatinized starch as a binder and secondary disintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate at the lowest level that provides acceptable lubrication

The formulation should use a controlled preblend for trandolapril. Geometric dilution, order-of-addition controls, and validated blend sampling are important because the API dose is small relative to total tablet weight.

Lactose-free opportunity

A lactose-free formulation could replace lactose with combinations of microcrystalline cellulose, mannitol, dibasic calcium phosphate, or starch-based fillers. The commercial benefit is mainly procurement flexibility and access to patients who avoid lactose-containing medicines. The tradeoff is that each substitute changes tablet density, dissolution, hygroscopicity, and compression behavior.

Mannitol may improve mouthfeel but increases cost and can change compaction characteristics. Dibasic calcium phosphate can improve flow and hardness but may create different dissolution behavior and compatibility considerations. A lactose-free product has a clearer commercial proposition if it also provides a measurable manufacturing or supply advantage.

Sodium-free and low-sodium positioning

MAVIK is not an effervescent product and does not require a sodium-containing excipient system. A manufacturer can avoid sodium-based processing aids and position the formulation as suitable for low-sodium product portfolios. This is unlikely to create meaningful prescription demand on its own, but it may simplify hospital formulary and institutional procurement discussions.

What formulation patents protect MAVIK or trandolapril?

The commercially relevant formulation protection for MAVIK is limited because the product is an old small-molecule tablet with established generic competition. The core trandolapril compound and early product patents would have expired before the current generic market.

IP category	Current commercial relevance
Trandolapril compound claims	Historical protection; expired
Original immediate-release tablet claims	Historical protection; expired or no longer a material barrier
Method-of-use claims for hypertension	Limited value against ordinary generic substitution
Combination-product claims involving verapamil	Relevant only to trandolapril/verapamil products
Manufacturing or process patents	Potentially relevant if a newer process is independently patented
Excipient-specific formulation patents	Possible for new products, but not inherent to the legacy MAVIK product
Trade secrets	Potential value in process controls, scale-up, and analytical methods

No patent should be assumed to block a trandolapril generic solely because a historical MAVIK formulation was used. A launch assessment requires a current FDA Orange Book review, patent-family search, and jurisdiction-specific freedom-to-operate analysis.

What is the Orange Book status of MAVIK?

MAVIK has no meaningful remaining brand exclusivity based on the age of its approval and the presence of generic trandolapril products. Any remaining Orange Book entries must be checked against the current FDA publication because listings can change through delisting, patent expiration, or product discontinuation.[2]

The relevant regulatory questions are:

1. Whether the reference listed drug remains actively marketed.
2. Which trandolapril product is the current reference listed drug.
3. Whether any listed patents remain unexpired.
4. Whether an ANDA applicant must submit a Paragraph IV certification.
5. Whether a 30-month stay or other litigation-related delay applies.

For a legacy product such as MAVIK, the more likely path is a Paragraph III certification or a section viii statement where applicable, rather than a commercially meaningful patent challenge.

When does MAVIK lose exclusivity and what is the generic entry position?

MAVIK lost practical market exclusivity years ago. Its commercial exclusivity is distinct from the formal expiration of individual patents or regulatory exclusivity periods.

Exclusivity type	MAVIK assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No material current barrier
New formulation exclusivity	No known market-blocking protection for the legacy tablet
Patent exclusivity	Historical, not a current barrier to ordinary generic entry
Generic entry	Established

The main launch risk is therefore not patent delay. It is market size, API sourcing, price erosion, bioequivalence execution, and the ability to secure pharmacy and wholesaler listings.

Which companies are challenging or competing with MAVIK?

Generic trandolapril competition has historically included multiple U.S. ANDA manufacturers and labelers. The competitive field can change because products are withdrawn, transferred, or placed in intermittent supply.

The most relevant competitors are:

• Generic manufacturers offering trandolapril tablets
• Suppliers of adjacent ACE inhibitors, including lisinopril, enalapril, ramipril, and perindopril
• Combination-product suppliers of trandolapril and verapamil
• Contract manufacturers able to produce low-dose, high-uniformity tablets

The strongest commercial substitutes are not necessarily other trandolapril products. Lisinopril and enalapril are more established generic ACE inhibitors with broader prescriber familiarity and larger market bases. A trandolapril entrant therefore needs a supply, contracting, or formulation advantage.

What patent litigation and Paragraph IV risks affect trandolapril?

No major current litigation barrier is inherent in the legacy MAVIK tablet. Paragraph IV risk would arise only if a current, unexpired patent were listed for the reference product or an associated formulation.

Potential litigation targets could include:

• A newly patented modified-release formulation
• A fixed-dose trandolapril combination
• A specialized tablet coating or stability system
• A manufacturing process that materially differs from the legacy process
• A method-of-use claim directed to a newly defined patient population

A conventional immediate-release generic that relies on expired composition and use claims generally has lower litigation exposure. The applicant still must confirm current Orange Book listings and patent-family status before filing.

What manufacturing and IP barriers exist for trandolapril?

The most important barriers are technical rather than patent-based.

Low-dose uniformity

Trandolapril tablets contain a small amount of API. Inadequate preblending can produce out-of-specification assay or content uniformity results. The process should control particle-size distribution, electrostatic behavior, blend time, and hopper residence time.

Moisture and hydrolysis

As an ester prodrug, trandolapril requires stability evaluation under heat and humidity. Moisture exposure can affect API degradation, dissolution, and tablet physical properties. Packaging should be selected from stability data rather than cost alone. High-barrier blister packaging may be preferable to conventional bottles where regional humidity is high.

Lubrication sensitivity

Excess magnesium stearate can reduce wettability and slow dissolution. The formulation should establish a narrow lubrication window through design-of-experiments work.

Scale-up

Scale-up risks include segregation during transfer, inconsistent granule density, compression-force changes, and differences in tablet ejection. These risks can be reduced through controlled bulk density, validated transfer steps, and in-process testing.

What commercial opportunities exist for MAVIK excipient reformulation?

1. Cost-optimized generic tablet

A standard immediate-release tablet using lactose, microcrystalline cellulose, crospovidone, starch, colloidal silicon dioxide, and magnesium stearate is the lowest-risk route. The opportunity depends on API cost, manufacturing efficiency, and reliable supply rather than formulation novelty.

2. Lactose-free product

A lactose-free trandolapril tablet can support institutional tenders and patient-sensitive portfolios. The product must demonstrate equivalent dissolution and bioequivalence. The opportunity is niche but practical.

3. High-barrier packaging

A manufacturer can differentiate through packaging designed for humid markets. This is relevant for export markets and procurement systems where product degradation or tablet softening has caused supply problems.

4. Trandolapril/verapamil combination

The historical TARKA product combined trandolapril with sustained-release verapamil. A combination product has greater formulation complexity because it must manage two APIs, different release requirements, dose strengths, and bioequivalence expectations. It may offer more differentiation than a single-ingredient generic, but it also carries higher development and regulatory costs.

5. Regional licensing and contract manufacturing

Because the product is mature, opportunities may exist in territories where trandolapril availability is limited or where local production is required. A platform manufacturer could license a dossier, supply tablets in bulk, or provide finished-dose manufacturing to regional marketing authorization holders.

How does trandolapril compare with competing ACE inhibitors?

Product	Commercial position	Formulation opportunity	Generic risk
Trandolapril	Mature, smaller market	Lactose-free tablet, packaging, combination product	High
Lisinopril	Large, established generic market	Standard tablet and solution	High
Enalapril	Broad use and long generic history	Tablet and oral solution	High
Ramipril	Strong cardiovascular positioning	Capsule and tablet platforms	High
Perindopril	Established in selected markets	Salt and formulation differentiation	High

Trandolapril is unlikely to win on price alone against larger ACE inhibitor markets. Its best opportunities are supply reliability, differentiated excipient selection, combination-product development, and targeted geographic commercialization.

What is the revenue exposure for a MAVIK reformulation?

Public revenue data for the historical MAVIK brand should not be treated as a reliable proxy for current trandolapril opportunity. The brand is mature, genericized, and no longer comparable with protected branded cardiovascular products.

A commercial model should instead use:

• U.S. and target-country prescription volume
• Number of active generic suppliers
• Average selling price by strength
• Wholesaler and pharmacy deductions
• API cost and minimum order quantity
• Packaging cost
• Stability and bioequivalence development cost
• Probability of supply interruptions among incumbent suppliers

A low-volume product can still be commercially attractive if there are few active suppliers, recurring backorders, or institutional demand. Conversely, a technically simple formulation may be unattractive if price erosion is severe.

Is there biosimilar risk for MAVIK?

No. Trandolapril is a chemically synthesized small molecule, not a biologic. Biosimilar regulation does not apply. Competition occurs through ANDAs, national generic pathways, or other small-molecule approval routes depending on jurisdiction.

What is the FDA regulatory pathway for a new trandolapril product?

A conventional U.S. generic would generally use an ANDA under section 505(j). The application would need to address:

• Pharmaceutical equivalence
• Bioequivalence
• Assay and content uniformity
• Dissolution across relevant media
• Stability
• Impurity profile
• Manufacturing controls
• Container-closure suitability
• Labeling consistency with the reference product

A reformulated product with a different excipient system may still qualify for an ANDA if it meets the applicable requirements and does not introduce a clinically meaningful difference. A new dosage form, new route, or materially different release profile may require a different regulatory strategy.

How strong is the MAVIK patent estate?

The legacy MAVIK patent estate is commercially weak for blocking purposes. The compound and ordinary immediate-release tablet are mature technologies. A new entrant should focus its IP strategy on genuinely differentiated products, such as:

• Improved moisture-stability compositions
• Novel fixed-dose combinations
• Modified-release systems
• Patient-specific dosage forms
• Manufacturing processes that produce a measurable quality or cost advantage

A patent application covering only routine substitution of one common diluent for another is unlikely to provide durable commercial protection unless the formulation produces unexpected and defensible performance.

Key Takeaways

• MAVIK contains trandolapril, an established ACE inhibitor supplied as an immediate-release tablet.
• The legacy formulation uses conventional excipients, including lactose, microcrystalline cellulose, starch, crospovidone, colloidal silicon dioxide, and magnesium stearate.
• The principal development challenge is low-dose content uniformity, followed by moisture stability and dissolution control.
• Practical opportunities include a low-cost generic, lactose-free formulation, high-barrier packaging, and trandolapril/verapamil combination products.
• Patent and exclusivity barriers are not the main risks for a new trandolapril entrant.
• Commercial success depends on market volume, supplier concentration, API economics, procurement access, and reliable supply.
• Trandolapril has no biosimilar pathway because it is a small-molecule drug.
• Current Orange Book listings, ANDA activity, and any live patent claims require verification against the latest FDA records before launch or investment decisions.

FAQs

Is MAVIK still marketed in the United States?

MAVIK is a legacy trandolapril brand with generic competition. Commercial availability of the branded product and individual generic products can vary by supplier and market.

Can a company launch a lactose-free trandolapril tablet?

Yes. A lactose-free formulation is technically feasible, but it must meet bioequivalence, dissolution, stability, and manufacturing requirements applicable to the chosen regulatory pathway.

Does trandolapril require special packaging?

Trandolapril products should undergo humidity and temperature stability testing. A high-barrier blister or bottle may be justified if the formulation or target market shows moisture sensitivity.

Is trandolapril/verapamil more commercially attractive than trandolapril alone?

It may provide greater differentiation, but the product requires more complex formulation development and regulatory testing because verapamil has its own dose, release, and bioequivalence requirements.

What is the main generic launch risk for trandolapril?

The main risk is weak or unstable economics caused by limited demand, established generic competition, price erosion, API procurement costs, and insufficient wholesaler or institutional access.

References

1. U.S. Food and Drug Administration. (n.d.). MAVIK (trandolapril) tablets prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Bioequivalence and product quality requirements.
4. U.S. Food and Drug Administration. (n.d.). TARKA (trandolapril and verapamil hydrochloride) extended-release tablets prescribing information.